A Woman with a Long History of Smoking and a Debilitating Dry Cough by N. D. Potskhverashvili, N. I. Kokina, E. L. Bueverova, O. Yu. Zolnikova, A. S. Cherenda, V. A. Morozova, M. V. Feldsherov, A. P. Kiryukhin, P. V. Pavlov

“…Surgical treatment was performed at the Sechenov University surgical hospital: right-sided hemicolectomy with D2 lymph dissection (removal of epicolic, paracolic, mesocolic lymph nodes); adjuvant chemotherapy was prescribed. The patient is under the supervision of an oncologist and a coloproctologist.Conclusion. …”
Get full text

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials by Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren

“…Conclusion: The addition of PARPi in the chemotherapy regimen for patients with SCLC results in increased PFS and ORR, with no difference in OS and an increased risk of TEAEs. …”
Get full text

Costs and Resource Use Among Patients with Cervical Cancer, Cervical Intraepithelial Neoplasia, and Genital Warts in Algeria by Ali-Chakib Bennacef, Aomar Ammar Khodja, Fadl Allah Abou-Bekr, Tidiane Ndao, Ryan Holl, Goran Benčina

“…Treatments used regularly or always for cervical cancer included chemotherapy (80%), hysterectomy (70%), and radiation (70%). …”
Get full text

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based... by Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade

“…**Background:** Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. …”
Get full text

The effect of ileostomy closure timing on low anterior resection syndrome in patient who underwent low anterior resection for rectal cancer by Hemn Hussain Kaka Ali, Qalandar Hussein Abdulkarim, Karzan Seerwan, Barham M. M .Salih, Omar H Ghalib Hawramy, Dara Ahmed Mohammed, Syamand Orhaman Ahmed

“…Ileostomy had been done to protect low lying Colo-rectal anastomosis, closure of ileostomy had been delayed in some patients due to patient own will, surgical complications (anastomotic leak) or coarse of chemotherapy. This study aimed to find the effect of temporary ileostomy on post-operative bowel defunction which is called Low anterior resection syndrome (LARS), and include; urgency, difficulty in emptying of bowel, and incontinence for feces and flatus.  …”
Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Patients with DLBCL (vs HGBCL), complete response before infusion, prior autologous or allogeneic haematopoietic stem cell transplant and lactate dehydrogenase (LDH) within normal limits experienced more favourable efficacy outcomes, and those with Eastern Cooperative Oncology Group performance status of ≥2, ≥3 prior lines of therapy, elevated LDH and fludarabine-based lymphodepleting chemotherapy experienced less favourable safety outcomes.Conclusions This real-world study of tisagenlecleucel for patients with R/R DLBCL/HGBCL shows consistent efficacy and better safety outcomes than the pivotal trial. …”
Get full text

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era by Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon

“…Growing evidence indicates surgery with adjuvant or neoadjuvant chemotherapy (SC) may be superior to non-surgical treatments. …”
Get full text

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACO... by David Malka, Philippe Laramée, Mondher Toumi, Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, Emmanuelle Samalin

“…Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOLFIRI (folinic acid, fluorouracil and irinotecan) or irinotecan). …”
Get full text

Stent as a bridge to surgery for malignant colonic obstruction: a retrospective study on survival and outcomes by Thanawin Wong, Tanawat Pattarapuntakul, Nisa Netinatsunton, Jaksin Sottisuporn, Thanapon Yaowmaneerat, Wongsakorn Chaochankit, Siriboon Attasaranya, Pimsiri Sripongpun, Naichaya Chamroonkul, Viraksakdi Chongsuvivatwong

“…Baseline characteristics were similar except for ASA classification and chemotherapy rates. The median OS was 56.1 months, with no significant differences in OS (51.4 vs. 61.0 months, p = 0.67) or 5-year DFS (53.8% vs. 59.9%, p = 0.32) between the two groups. …”
Get full text

Factors determining primary or delayed surgery for unilateral, non-metastatic Wilms tumor: a multicentric Egyptian study by Ahmed Elgendy, Amr Abdelhamid AbouZeid, Mohamed El-Debeiky, Shaimaa Abdelsattar Mohammad, Marwa Romeih, Ahmed Ebeed, Mohamed Abouheba, Mohammed Hamada Takrouney, Mahmoud Mostafa, Ahmed Khairi, Osama El-Naggar, Sameh Shehata

“…Primary nephrectomy was performed in 62 patients (55.4%), while 50 (44.6%) underwent delayed resection after biopsy and neoadjuvant chemotherapy. Tumors larger than 12 cm and tumors crossing the midline were reported in 38.5% and 35% of all patients, respectively. …”
Get full text

Evaluating the risk of underdiagnosis of invasive breast cancer in needle biopsy-diagnosed ductal carcinoma in situ eligible for radiofrequency ablation by Hideo Shigematsu, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Koji Arihiro, Morihito Okada

“…Adjuvant endocrine therapy and chemotherapy were administered to 26 (65.0%) and 6 (15.0%) of the underdiagnosed lesions, respectively. …”
Get full text

Two rare cases of primary clear cell adenocarcinoma of the urethra: clinical experience, case report and literature review by Bohao Jiang, Jiyuan Hu, Benqiao Wang, Xujia Liu, Ling Tong, Yitong Xu, Hao Zhang

“…Case 1 undergone progression 6 months after initial treatment with transurethral resection and chemotherapy with a 15-month overall survival. In contrast, the prognosis of case 2 remained uneventful 10 months after surgery without recurrence. …”
Get full text

Case report: Unraveling a unique case of male occult breast cancer with axillary intricacies and a comprehensive literature dive by Xintong Xie, Xiangyi Kong, Xiangyi Kong, Hongnan Jiang, Jidong Gao, Jidong Gao

“…His treatment involved a multidisciplinary approach, including HER2-targeted therapy, chemotherapy, axillary lymph node dissection, and radiotherapy. …”
Get full text

Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis by Hao Chen, Masashi Ishihara, Hiroki Kazahari, Ryusuke Ochiai, Shigeru Tanzawa, Takeshi Honda, Yasuko Ichikawa, Nobuyuki Horita, Hisashi Nagai, Kiyotaka Watanabe, Nobuhiko Seki

Get full text

Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p/STAT1 by Baocheng Xie, Peishan Wu, Hongyu Liu, XiangDi Yang, Linxuan Huang

“…Targeting MIR4435-2HG presents a promising therapeutic approach to regulate CSCs and improve the efficacy of chemotherapy in pancreatic cancer.…”
Get full text

Odor symptom management in patients with malignant wounds in Mali: the use of a cinnamon dressing by Charlotte Ngô, Fatoumata M Sidibe, Sophie Goossens, Dianeko Zenabou Tapa, Irène Kriegel, Abdramane A Kone, Moussa Bathily, Hamidou D Doumbia, Claire Rieux, Isabelle Fromantin

“…The cinnamon dressing had no effect on appetite, but most of the patients were undergoing palliative chemotherapy, which may account for this result. Conclusion The use of innovative dressings is feasible, even in very deprived contexts, and might decrease the discomfort linked with unpleasant odors in tumoral wounds. …”
Get full text

Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and... by Yulin Shi, Yang Yu, Jiahan Zhao, Linan Huang, Qingyang Wang, Qi Sun, Lijuan Liu, Changgang Sun

“…The model demonstrated robust predictive capability in both the TCGA cohort and an external cohort, with the low-risk group exhibiting elevated expression of immunological checkpoint molecules and immune cell infiltration, as well as better responses to immunotherapy and chemotherapy. Furthermore, these four biomarkers were found to be highly expressed on CD8+ Tex and were associated with cellular communication efficiency. …”
Get full text

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma by Mengdi Fu, Huimei Zhou, Jiaxin Yang, Dongyan Cao, Zhen Yuan

“…Abstract Ovarian clear cell carcinoma (OCCC) is resistant to chemotherapy, with limited treatment options for advanced and recurrent disease. …”
Get full text

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

“…Methods This single‐center, prospective, randomized, open‐label study was conducted, from January 2021 to December 2022, in Beijing Friendship Hospital, Capital Medical University, and participants were randomly assigned (1:1) to either the inosine (trial) or non‐inosine (control) group that received inosine (dosage: 0.2 g, three times/day) + PD‐1/PD‐L1 inhibitor or only PD‐1/PD‐L1 inhibitor ± targeted ± chemotherapy, respectively. Efficacy was assessed every 6 weeks (i.e., after every two–three treatment cycles). …”
Get full text

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer by Maria Elena Lacruz, Saskia Thies, Andrea Schmidt-Pokrzywniak, Ian Wittenberg, Tobias Engler, Fabian Reinwald, Monika Klinkhammer-Schalke, Sylke Ruth Zeissig, Bianca Franke, Kerstin Weitmann, Atanas Ignatov

“…Pathological complete response (pCR) rates after neoadjuvant chemotherapy were highest in HER2-positive. HER2-low has higher hormone receptor positivity, distinguishing it from HER2-zero. …”
Get full text